115563
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
0.05% 阿托品治疗近视儿童的短期脉络膜和视网膜结构变化
Authors Yang Y , Luo Z, Wen L, Gao W, Deng Y, Tang X , Yang Z, Li X
Received 30 September 2025
Accepted for publication 30 December 2025
Published 15 January 2026 Volume 2026:20 570502
DOI https://doi.org/10.2147/OPTH.S570502
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Yousef Fouad
Yuanfang Yang,1– 5 Zhiwei Luo,3– 5 Longbo Wen,1– 3 Wenyu Gao,3– 5 Yuexiang Deng,3– 5 Xiangzhong Tang,3– 5 Zhikuan Yang,1– 7 Xiaoning Li1– 7
1Aier Academy of Ophthalmology, Central South University, Changsha, People’s Republic of China; 2Department of Optometry, Changsha Aier Eye Hospital, Changsha, People’s Republic of China; 3Research Department, Aier Institute of Optometry and Vision Science, Aier Eye Hospital Group, Changsha, People’s Republic of China; 4Hunan Province Optometry Engineering and Technology Research Center, Changsha, People’s Republic of China; 5Research Department, Hunan Province International Cooperation Base for Optometry Science and Technology, Changsha, People’s Republic of China; 6Aier Eye Hospital, Jinan University, Guangzhou, People’s Republic of China; 7School of Stomatology and Ophthalmology, Xianning Medical College, Hubei University of Science and Technology, Xianning, People’s Republic of China
Correspondence: Xiaoning Li, Aier Academy of Ophthalmology, Central South University, Changsha, People’s Republic of China, Email lixiaoning@aierchina.com Zhikuan Yang, Aier Academy of Ophthalmology, Central South University, Changsha, People’s Republic of China, Email yangzhikuan@aierchina.com
Purpose: To evaluate daily 0.05% atropine’s effects on structural changes in the choroid and retina in myopic children.
Methods: This prospective cohort study included 100 children aged 6– 15 years, of whom 83 completed 6-month follow-up. Participants received either nightly 0.05% atropine eyedrops or no pharmacologic treatment (all wore single-vision spectacles). Spherical equivalent (SE) and axial length (AL) were measured, and swept-source OCT angiography was used to assess choroidal thickness (CT), retinal thickness (RT), outer retinal layer (ORL), ganglion cell layer plus inner plexiform layer (GCL+IPL), inner nuclear layer (INL), peripapillary retinal nerve fiber layer (RNFL), choroidal vascular volume (CVV), choroidal vascular index (CVI), superficial and deep vascular complexes (SVC/DVC), and nerve fiber layer vascular density (NFVD).
Results: Atropine reduced myopia progression compared to controls (ΔSE: 0.11 vs − 0.30 D; ΔAL: 0.01 vs 0.17 mm; P < 0.001). In the atropine group, 55.56% showed SE improvement and 42.22% exhibited AL shortening. Significant increases were observed in macular CT, CVV, RT, ORL, GCL+IPL, INL, and peripapillary RT, ORL, and RNFL, whereas CVI, SVC, DVC, and NFVD remained unchanged. Changes in macular CT, CVV, RT, and GCL+IPL were positively correlated with ΔSE and negatively with ΔAL. Increases in ORL and peripapillary RNFL were negatively correlated with ΔAL.
Conclusion: Daily 0.05% atropine not only slowed myopia progression and axial elongation but also promoted thickening of choroidal and retinal layers. These structural changes suggest partial reversal of ocular growth, supporting the therapeutic role of atropine in myopia control.
Trial Registration: Chinese Clinical Trial Registry (ChiCTR2100043506, https://www.chictr.org.cn/showproj.html?proj=122214, registered 21 February 2021). This study represents a secondary analysis of the registered trial; the control group was drawn from an ethically approved observational cohort.
Keywords: 0.05% atropine eyedrops, myopia control, choroid, retina, OCTA
1Aier Academy of Ophthalmology, Central South University, Changsha, People’s Republic of China; 2Department of Optometry, Changsha Aier Eye Hospital, Changsha, People’s Republic of China; 3Research Department, Aier Institute of Optometry and Vision Science, Aier Eye Hospital Group, Changsha, People’s Republic of China; 4Hunan Province Optometry Engineering and Technology Research Center, Changsha, People’s Republic of China; 5Research Department, Hunan Province International Cooperation Base for Optometry Science and Technology, Changsha, People’s Republic of China; 6Aier Eye Hospital, Jinan University, Guangzhou, People’s Republic of China; 7School of Stomatology and Ophthalmology, Xianning Medical College, Hubei University of Science and Technology, Xianning, People’s Republic of China
Correspondence: Xiaoning Li, Aier Academy of Ophthalmology, Central South University, Changsha, People’s Republic of China, Email lixiaoning@aierchina.com Zhikuan Yang, Aier Academy of Ophthalmology, Central South University, Changsha, People’s Republic of China, Email yangzhikuan@aierchina.com
Purpose: To evaluate daily 0.05% atropine’s effects on structural changes in the choroid and retina in myopic children.
Methods: This prospective cohort study included 100 children aged 6– 15 years, of whom 83 completed 6-month follow-up. Participants received either nightly 0.05% atropine eyedrops or no pharmacologic treatment (all wore single-vision spectacles). Spherical equivalent (SE) and axial length (AL) were measured, and swept-source OCT angiography was used to assess choroidal thickness (CT), retinal thickness (RT), outer retinal layer (ORL), ganglion cell layer plus inner plexiform layer (GCL+IPL), inner nuclear layer (INL), peripapillary retinal nerve fiber layer (RNFL), choroidal vascular volume (CVV), choroidal vascular index (CVI), superficial and deep vascular complexes (SVC/DVC), and nerve fiber layer vascular density (NFVD).
Results: Atropine reduced myopia progression compared to controls (ΔSE: 0.11 vs − 0.30 D; ΔAL: 0.01 vs 0.17 mm; P < 0.001). In the atropine group, 55.56% showed SE improvement and 42.22% exhibited AL shortening. Significant increases were observed in macular CT, CVV, RT, ORL, GCL+IPL, INL, and peripapillary RT, ORL, and RNFL, whereas CVI, SVC, DVC, and NFVD remained unchanged. Changes in macular CT, CVV, RT, and GCL+IPL were positively correlated with ΔSE and negatively with ΔAL. Increases in ORL and peripapillary RNFL were negatively correlated with ΔAL.
Conclusion: Daily 0.05% atropine not only slowed myopia progression and axial elongation but also promoted thickening of choroidal and retinal layers. These structural changes suggest partial reversal of ocular growth, supporting the therapeutic role of atropine in myopia control.
Trial Registration: Chinese Clinical Trial Registry (ChiCTR2100043506, https://www.chictr.org.cn/showproj.html?proj=122214, registered 21 February 2021). This study represents a secondary analysis of the registered trial; the control group was drawn from an ethically approved observational cohort.
Keywords: 0.05% atropine eyedrops, myopia control, choroid, retina, OCTA